Articles filed under Treatment Options.
Any patient with metastatic breast cancer (MBC) will be familiar with the concept of ‘treatment lines’. Unlike primary breast cancer, where you undergo chemotherapy for a fixed time period, after…
Read more
METUPUK’ Breast Cancer Awareness Month campaign for October across the UK and on social media channels. Continuing the synergy with The Darker Side of Pink travelling campaign highlighting the 31…
Read more
A cancer drug which received standing ovation from the Global Medical Community is being withheld from NHS breast cancer patients. METUPUK are devastated by NICE decision not to recommend the drug…
Read more
METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict treatment lines are affecting…
Read more
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous…
Read more
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic…
Read more
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or…
Read more
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the…
Read more
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted:…
Read more
Hi. My name is Gita and I have been a Therapeutic Radiographer for nearly 30 years. I’d like to share my professional and personal experiences of treating both primary and secondary breast cancer.
Read more
*METUPUK are delighted for the approval of Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received one or more prior anti-HER2…
Read more
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer. Piqray is an exciting new…
Read more
